Official-source baseline for AbCellera Biologics using SEC submissions, SEC company facts, the FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, filed company presentations, and 2026 proxy materials.
References
Sources used in this report
SEC issuer filing indexSEC submissions index for AbCellera Biologics Inc.2026-05-13 · CIK, issuer identity, fiscal year end, and current filing selection.SEC company factsSEC XBRL company facts for AbCellera Biologics Inc.2026-05-13 · Standardized cross-check of reported financial metrics.Annual reportAbCellera FY2025 Form 10-K2026-02-24 · Business model, partner economics, competition, risks, facilities, liquidity, R&D strategy, and FY2025 financials.Quarterly reportAbCellera Q1 FY2026 Form 10-Q2026-05-11 · Latest liquidity, revenue, expense, net loss, cash flow, program status, and runway statement.Company results releaseAbCellera Q1 2026 results release2026-05-11 · Q1 2026 operating metrics, liquidity, ABCL635 interim Phase 1 data, Phase 2 timing, and pipeline updates.Company investor presentationAbCellera Q1 2026 business update presentation2026-05-11 · Company-controlled product, pipeline, and market context; management estimates labeled as such.Company results releaseAbCellera FY2025 results release2026-02-24 · FY2025 operating and liquidity context.Company investor presentationAbCellera FY2025 business update presentation2026-02-24 · Company-controlled pipeline and platform context.Proxy statementAbCellera 2026 DEF 14A proxy statement2026-04-29 · Governance, board leadership, committees, cybersecurity oversight, insider policy, clawback policy, and code of conduct.Company investor presentationAbCellera January 2026 corporate overview2026-01-14 · Supporting company-controlled strategic and pipeline overview.